drugset / Trial / NCT01039519

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

NCT01039519

Phase 2 Completed 27 enrolled Synta Pharmaceuticals Corp.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.

Timeline

Start
2010-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule 200 mg/m2 Intravenous